Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040
In this cross-sectional study, MASLD-related mortality increased rapidly between 2006 and 2023 and was projected to rise over the next 20 years, with the largest disparities among those aged 65 years and older, among non-Hispanic White and Hispanic individuals, and among nonmetropolitan populations.
Authors
- Ramsey Cheung (ORCID: https://orcid.org/0000-0002-0211-7013)
- Mindie H. Nguyen (ORCID: https://orcid.org/0000-0002-6275-4989)
- Fanpu Ji (ORCID: https://orcid.org/0000-0002-1463-8035)
- S. Van Der Linden (ORCID: https://orcid.org/0000-0003-1810-0790)
- Scott D. Barnet
- Charles R. Levesley (ORCID: https://orcid.org/0009-0009-8119-1091)
- Zhangjie Yang (ORCID: https://orcid.org/0000-0002-1817-8822)
- Xinyuan He (ORCID: https://orcid.org/0009-0007-3631-334X)
- Xinrong Zhang (ORCID: https://orcid.org/0000-0002-8393-8904)
Institutions
- Palo Alto University (US)
- VA Palo Alto Health Care System (US)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Stanford Medicine (US)
- Xi'an Jiaotong University (CN)
- Stanford University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.16367
- Citations
- 12
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 16.25
Funders
- Pfizer
- AstraZeneca
- Gilead Sciences
- National Cancer Institute